Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775434 · ClinicalTrials.gov registry record · Phase 1
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis and Eczema, sponsored by AOBiome.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 6
- Study locations
NCT03775434 is a Phase 1 study of Atopic Dermatitis and Eczema that has completed, run by AOBiome. The registered enrollment target is 28 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT03775434, a Phase 1 study of Atopic Dermatitis and Eczema, has completed, sponsored by AOBiome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 6
- Study locations
Study Summary
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b
Conditions Studied
Interventions
- DRUG Experimental: B244
Study Locations (6)
Arkansas
- Dermatology Trial Associates - Bryant
California
- L.A. Universal Research Center, Inc. - Los Angeles
Indiana
- The Indiana Clinical Trials Center - Plainfield
Minnesota
- Minnesota Clinical Study Center - Fridley
Nebraska
- Skin Specialists, PC - Omaha
Virginia
- Virginia Clinical Research, INC - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2019-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03775434
The ClinicalTrials.gov registry entry for NCT03775434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower). The listed sponsor is AOBiome, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Experimental: B244 is the first listed.
NCT03775434 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arkansas, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT03775434 about?
NCT03775434 is a clinical study titled "A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis". An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b
What is the current status of trial NCT03775434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-12-07. Estimated completion is 2019-06-10.
What conditions does trial NCT03775434 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT03775434?
The interventions under investigation include: Experimental: B244 (DRUG).
Who is sponsoring clinical trial NCT03775434?
This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03775434 being conducted?
This trial has 6 study locations across Arkansas, California, Indiana, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.